Mallinckrodt plc is a specialty pharmaceutical company that develops, manufactures and commercializes therapies for complex and critical medical conditions. Its portfolio has historically included branded and generic specialty pharmaceuticals, controlled substances, hospital products and therapies used in rare diseases, immunology, neurology, respiratory care and pain management.
The company’s products have included Acthar Gel, a repository corticotropin injection used for certain inflammatory and autoimmune conditions; INOmax, an inhaled nitric oxide therapy used in neonatal respiratory care; and Therakos photopheresis systems and related products used in extracorporeal photopheresis. Mallinckrodt has also marketed hospital-based products such as Ofirmev, an intravenous acetaminophen formulation, along with other specialty and generic medicines.
Mallinckrodt was established as an independent company following the 2013 separation of Covidien’s pharmaceuticals business. It expanded its specialty portfolio through acquisitions, including the purchase of Questcor Pharmaceuticals, the developer of Acthar Gel, in 2014. The company has served customers in the United States and selected international markets through hospitals, specialty pharmacies, physicians and other healthcare providers.
Mallinckrodt and certain subsidiaries have undergone significant financial restructuring, including Chapter 11 proceedings, amid substantial debt obligations and legal liabilities related to its historical opioid business. The company’s operations and product portfolio have changed over time as part of those restructuring efforts and broader strategic reviews.
AI Generated. May Contain Errors.
Free MNKKQ Stock Alerts